CNS Pharmaceuticals (CNSP) Projected to Post Earnings on Wednesday

CNS Pharmaceuticals (NASDAQ:CNSP) is anticipated to announce its Q3 2026 results on Wednesday, November 18th. Analysts expect the company to post earnings of ($0.27) per share for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 20, 2026 at 9:30 AM ET.

CNS Pharmaceuticals (NASDAQ:CNSP) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.14).

CNS Pharmaceuticals Price Performance

Shares of NASDAQ:CNSP opened at $3.85 on Wednesday. CNS Pharmaceuticals has a 52 week low of $1.90 and a 52 week high of $10.54. The firm has a 50 day moving average of $5.11 and a 200 day moving average of $4.51.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, CNS Pharmaceuticals currently has a consensus rating of “Sell”.

CNS Pharmaceuticals Company Profile

CNS Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for primary and metastatic cancers of the central nervous system. The company is headquartered in Houston, Texas, and its shares trade on the Nasdaq Capital Market under the symbol CNSP. CNS Pharmaceuticals’ lead product candidate is berubicin, an anthracycline designed to cross the blood-brain barrier. The company is evaluating berubicin as a potential treatment for glioblastoma multiforme, an aggressive and often fatal form of brain cancer for which treatment options remain limited.